Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
A Casadevall, MJ Joyner, LA Pirofski… - Expert review of …, 2023 - Taylor & Francis
Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …
COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis
JW Senefeld, M Franchini, C Mengoli… - JAMA Network …, 2023 - jamanetwork.com
Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …
mortality associated with coronavirus disease 2019 (COVID-19) because they less …
[HTML][HTML] Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review
Background Most patients with SARS-CoV-2 are non-infectious within 2 weeks, though viral
RNA may remain detectable for weeks. However there are reports of persistent SARS-CoV-2 …
RNA may remain detectable for weeks. However there are reports of persistent SARS-CoV-2 …
[HTML][HTML] Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection
E Li, Q Han, J Bi, S Wei, S Wang, Y Zhang… - Frontiers in …, 2023 - frontiersin.org
The emergence of SARS-CoV-2 variants stresses the continued need for broad-spectrum
therapeutic antibodies. Several therapeutic monoclonal antibodies or cocktails have been …
therapeutic antibodies. Several therapeutic monoclonal antibodies or cocktails have been …
Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single …
A Oliva, F Cancelli, A Brogi, A Curtolo… - New …, 2022 - iris.uniroma1.it
Convalescent plasma (CP) therapy might be effective in patients with haematological
malignanciesand B-cell depletion. We report a single-centre experience of COVID-19 …
malignanciesand B-cell depletion. We report a single-centre experience of COVID-19 …
Challenges of mesenchymal stem cells in the clinical treatment of COVID-19
L Li, X Zhang, Y Wu, C Xing, H Du - Cell and Tissue Research, 2024 - Springer
Abstract The 2019 coronavirus disease (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has brought an enormous public health burden to …
syndrome coronavirus 2 (SARS-CoV-2) has brought an enormous public health burden to …
[HTML][HTML] Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
D Totschnig, D Doberer, R Haberl, C Wenisch… - IDCases, 2022 - Elsevier
Background Patients having undergone B-cell-depletion with anti-CD20-antibodies have a
higher risk of mortality, delayed viral clearance and prolonged infection due to severe acute …
higher risk of mortality, delayed viral clearance and prolonged infection due to severe acute …
Persistent SARS-CoV-2 infection in a patient with nephrotic syndrome under rituximab therapy: Successful treatment with a combination of remdesivir and monoclonal …
A Shimizu, I Shirai, K Ogawa, A Miura, K Haruhara… - Internal …, 2022 - jstage.jst.go.jp
Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic
syndrome, but there is concern about infections caused by humoral immunodeficiency. We …
syndrome, but there is concern about infections caused by humoral immunodeficiency. We …
[HTML][HTML] A Teaching Case: Persistent COVID-19 Pneumonia Resembling Cryptogenic Organizing Pneumonia in a Patient With Remitted Lymphoma
T Yanagihara, M Kadowaki, J Otsuka, A Ishimatsu… - Cureus, 2023 - ncbi.nlm.nih.gov
We report a case of a female patient in her 50s, previously diagnosed with follicular
lymphoma (now in complete remission), who was admitted to our hospital due to antibiotic …
lymphoma (now in complete remission), who was admitted to our hospital due to antibiotic …
Antibody response and intra‐host viral evolution after plasma therapy in COVID‐19 patients pre‐exposed or not to B‐cell‐depleting agents
D Gachoud, T Pillonel, G Tsilimidos… - British Journal of …, 2022 - Wiley Online Library
Administration of plasma therapy may contribute to viral control and survival of COVID‐19
patients receiving B‐cell‐depleting agents that impair humoral immunity. However, little is …
patients receiving B‐cell‐depleting agents that impair humoral immunity. However, little is …